Skip to main content
. 2019 Nov 19;2019(11):CD012187. doi: 10.1002/14651858.CD012187.pub2

NCT03431285.

Trial name or title Ketamine for acute painful crisis in sickle cell disease patients
Methods Allocation: randomized
Controlled: active comparator
Blinding: triple
Arm: 3 arm, parallel groups
Centre: single
Study duration: 1 January 2018 (recruiting, ongoing)
Participants Inclusion criteria: known diagnosis of sickle cell disease based on sickle cell tests and haemoglobin electrophoresis; acute onset of painful crises, defined as having an onset within 7 days
Exclusion criteria: healthy volunteers; other comorbidities; allergies to study medication; pregnancy or breastfeeding
Baseline characteristics
N: 264 participants, still recruiting
Gender: men and women
Ages: 18–60 years
Setting and location: Dammam University, Saudi Arabia
Interventions Treatment group: morphine
Control group: ketamine
Other group: standard intravenous hydration
Outcomes Primary outcomes
  • Pain


Secondary outcomes
  • Length of stay in emergency department

  • Cumulative use of opioids

  • Rate of hospital admission

  • Adverse effects

Starting date 1 January 2018
Contact information Mohammed SS Alshahrani, MD, Dammam, Eastern, Saudi Arabia, 31952
Notes